9459 Urgency vs. Optimization in AML Enduring Pretest

Urgency vs. Optimization in the Treatment of AML: Pharmacological Advances and the Role of HCT Pretest

1. Julie is a 62-year-old woman diagnosed with CN-AML (ASXL1+) now in morphologic CR1 and planned to proceed to matched unrelated stem cell transplant. Her pre-admission bone marrow biopsy confirms ongoing morphologic CR1, but the ASCL1 mutation is still detectable (allele frequency 6%). How should you proceed? *This question is required.

2. For a 66-year-old patient with newly diagnosed AML with a FLT3 ITD mutation, who is fit for induction, reasonable treatment options include: *This question is required.